Late-stage Parkinson's disease represents the culmination of progressive dopaminergic neurodegeneration, characterized by severe neuronal loss exceeding 70-80% of substantia nigra pars compacta (SNc) neurons, widespread alpha-synuclein pathology, and profound dysfunction of surviving neurons. This page provides comprehensive information about the neuropathological features, cellular changes, therapeutic challenges, and research directions related to end-stage PD dopaminergic neurons. [1]
Late-stage Parkinson's disease typically develops after 10-15 years of disease progression and is characterized by: [2]
The pathological changes in late-stage PD reflect both the primary neurodegenerative process and secondary complications from chronic dopaminergic therapy. [3]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000700 | dopaminergic neuron |
| Database | ID | Name | Confidence | [4]
|----------|----|------|------------| [5]
| Cell Ontology | CL:0000700 | dopaminergic neuron | Medium | [6]
The hallmark of late-stage PD is dramatic dopaminergic neuron loss: [7]
Quantitative Changes:
90% loss of striatal dopamine terminals
Qualitative Changes:
Lewy pathology becomes extensive in late-stage PD:
Lewy Bodies:
Lewy Neurites:
Distribution:
Tau Pathology:
Neuroinflammation:
Remaining dopaminergic neurons attempt to compensate:
Functional Compensations:
Structural Compensations:
Despite compensation, neurons face overwhelming stress:
Mitochondrial Dysfunction:
Calcium Dysregulation:
Proteostasis Failure:
Senescent changes in surviving neurons:
Chronic microglial activation characterizes late-stage PD:
Activated Phenotype:
Phagocytic Activity:
Reactive astrocytes in PD:
Proliferative Response:
Functional Changes:
Treatment challenges in late-stage PD:
Motor Complications:
Non-Motor Symptoms:
Device-Assisted Therapies:
Pharmacological Strategies:
Emerging treatments for advanced PD:
Disease-Modifying Therapies:
Neuroprotective Strategies:
Tracking progression in late-stage PD:
Cerebrospinal fluid markers:
Motor and non-motor assessments:
Key research areas:
Preventing progression to late-stage PD:
Repair and replacement approaches:
The study of Late Stage Parkinson Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kordower et al. Disease duration and pathology in PD (2013). 2013. ↩︎
Fearnley & Lees Aging and Parkinson's disease (1991). 1991. ↩︎
Cheng et al. Progression of PD pathology (2010). 2010. ↩︎
[Kalia & Lang Parkinson's disease (2015)](https://doi.org/10.1016/S0140-6736(15). 2015. ↩︎
Obeso et al. Functional networks in PD (2017). 2017. ↩︎
Surmeier et al. Calcium and PD vulnerability (2017). 2017. ↩︎